Science creates value only when medical strategy, regulation, trial design, execution, access, capital and leadership work as one system.
MB&P provides CMO-level ownership of that system—from the first development thesis through lifecycle evidence and controlled global execution.
Observe the rhythm. Anticipate the break. Act before value is lost.
The protocol may satisfy Clinical Development. The country plan may satisfy Operations. The comparator may satisfy Regulatory. The budget may satisfy Procurement. Yet the complete programme can still produce an answer that is late, unaffordable, uninterpretable or irrelevant to patients, payers and investors.
Functional competence is not system performance. MB&P brings medical, regulatory, patient, payer, commercial, operational, leadership and capital perspectives into one decision system.
From Cutting-Edge Clinical Strategy: The P-Value Did Not Kill the Drug ↗
You may need one intervention. Your programme still needs one system. Each mandate begins with the problem you can see, but is examined in the context of the whole development architecture.
Accountable CMO-level ownership across clinical strategy, board decisions, medical governance, capital allocation and execution.
Define what must be learned, proven and decided before assumptions become locked into protocols, timelines and capital commitments.
Reconstruct why the evidence system is drifting, restore decision rights and protect interpretability before an expensive but unusable conclusion.
Align approval, reimbursement, patient value and future clinical relevance before pivotal assumptions become difficult to change.
Test whether the programme deserves more capital, which assumptions threaten value and what must change before financing, licensing or partnering.
Continue clinical development after launch through scientific authority, lifecycle evidence, external intelligence and insight-to-action governance.
Translate the clinical architecture into countries, sites, vendors, quality, data and timelines through one governed hub-and-spoke delivery model.
The client contracts with MB&P or Verum. We assemble and govern the regional CROs, clinical sites, laboratories, specialist vendors and healthcare partners required by the programme. One integrated plan, one risk and assumption register, one governance cadence and one escalation path connect strategy to delivery.
The spokes adapt to the programme. Accountability does not.
Senior ownership of the development thesis, evidence architecture and cross-functional decisions that determine programme value.
The accountable medical, project, quality and sponsor-facing execution hub through which the client contracts.
Qualified regional CROs, sites and specialist capabilities selected for the programme and governed through the same operating logic.
Map the evidence, execution and governance risks that threaten the next decision.
Correct the architecture before weak assumptions become embedded in cost and timelines.
Converge medical, regulatory, payer, operational, leadership and capital logic.
Govern delivery until the evidence remains interpretable at database lock and beyond.
Selected programme and partner-network outcomes. These figures show what disciplined design and governance can achieve; they are not universal guarantees. 29+ years · 100+ studies · Phase I–IV and lifecycle evidence · five-continent experience.
Start-up acceleration through governed hub-and-spoke execution.
Better fit between protocol assumptions, site reality and patient selection.
Coordinated multi-region execution under one governance logic.
A programme designed only for approval is already under-designed. Before launch, evidence must support regulatory claims, access, adoption, differentiation and the next capital decision. After launch, the product enters clinical life: comparative value, safety, place in therapy and future evidence questions become real.
Medical Affairs is not a marketing support layer. It is the continuation of clinical development across the product lifecycle.
From Precision in Practice: Technically Strong. Impact Low. Why Medical Affairs Must Lead ↗
A low initial budget can be built on best-case recruitment, underestimated activity, fragmented responsibilities and exclusions that become chargeable only after execution begins. The headline price wins the procurement decision. The assumptions determine the final spend.
Country selection is not a logistics choice. It changes patient access, site capability, recruitment, endpoint variability, duration, cost, generalisability and payer relevance. The country is part of the trial design.
The “Hybrid CRO Model” Is Misnamed ↗
The Estimand Under Stress ↗
People enter through the problem they recognise. Some begin with leadership. Some begin with Medical Affairs. Others begin with the complete clinical-development system. Each academy stands on its own. Together they reveal why functional expertise alone cannot govern a complex life-science outcome.
Judgement, truth-seeking, responsibility and leadership under uncertainty. It shows how leadership determines whether difficult evidence decisions are made early enough.
The integrative pathway built from the Clinical Development Excellence Canon: science, strategy, evidence, execution, access, Medical Affairs, leadership and lifecycle learning.
Scientific authority, lifecycle evidence, Field Medical intelligence and insight-to-action. It repositions Medical Affairs as post-launch clinical development rather than promotional support.
The recurring pattern is unusual breadth: senior medical judgement, operational realism, originality of thought and the ability to turn complexity into accountable decisions.
“He contributed to the development of the Phase II study design and protocol submission, was closely involved in selecting subcontractors, and supported us in achieving scientific advice from EMA.”
“He quickly earned the reputation of the ‘go-to’ expert among our teams. He would roll up his sleeves and convert strategy to action by working on deliverables.”
“A highly respected medical expert who also has deep and practical operational insight. Physicians with both capabilities are extremely rare and valuable.”
Bring one live decision, the next hard milestone and the time available. The first conversation will identify where the programme is most exposed, whether focused intervention can create material value and what the shortest credible next step should be.
The cost of senior judgement is visible. The cost of the wrong decision usually appears later.
